For children affected by OI with osteoporosis, Denosumab (an anti-resorption RANKL agent) has been shown to raise bone mineral density (BMD) without adverse effects and decreased fracture rates in a Japanese study, though there were only 8 participants and only 3 of these under 16 years [56]. The gene discussed is TNFSF11; the disease is osteoporosis.